The United Kingdom and the United States have concluded a major commercial pact that will keep zero import taxes on UK medicine products entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the NHS. This commitment secures that tariffs on these vital exports will remain at nothing for a period of 36 months.
This development is in response to earlier warnings to dramatically increase duties on patented pharmaceutical imports, with potential rates mentioned reaching 100%.
"This arrangement between the United Kingdom bolsters the global environment for new treatments and establishes much-needed fairness to transatlantic medicine commerce," a statement said.
Trade Significance
Pharmaceuticals constitute one of the Britain's largest exports to the US, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Export figures show that in the one-year period to the end of the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards employment, boosts capital expenditure and facilitates the UK to become a international leader for biotech and pharma," a minister stated.
Key UK Commitments
The agreement involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to raise overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, rebates were more than 20%.
Industry Background
The pact takes place against a ongoing tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
These tensions were heightened by arguments that American patients were paying a premium for the equivalent treatments than people in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been directed toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the previous ten-year period.
